FWBI ข่าวฟอเร็กซ์

First Wave BioPharma To Sell Niclosamide Program To Undisclosed Biopharmaceutical Company

First Wave BioPharma To Sell Niclosamide Program To Undisclosed Biopharmaceutical Company

Biopharmaceutical company First Wave BioPharma, Inc. (FWBI) announced Wednesday that it has entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and related conditions to an undisclosed biopharmaceutical company.
RTTNews | 518 วันที่ผ่านมา